Cited by 1,521HIV-related health complications and treatmentsHIV/AIDS drug development and treatmentLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

Open access

The DAD Study Group·2007·New England Journal of Medicine

DOI 10.1056/nejmoa062744

Open this paper in CoChat — free account

Abstract

BACKGROUND: We have previously demonstrated an association between combination antiretroviral therapy and the risk of myocardial infarction. It is not clear whether this association differs according to the class of antiretroviral drugs. We conducted a study to investigate the association of cumulative exposure to protease inhibitors and nonnucleoside reverse-transcriptase inhibitors with the risk of myocardial infarction. METHODS: We analyzed data collected through February 2005 from our prospective observational study of 23,437 patients infected with the human immunodeficiency virus. The incidence rates of myocardial infarction during the follow-up period were calculated, and the associations between myocardial infarction and exposure to protease inhibitors or nonnucleoside reverse-transcriptase inhibitors were determined. RESULTS: Three hundred forty-five patients had a myocardial infarction during 94,469 person-years of observation. The incidence of myocardial infarction increased from 1.53 per 1000 person-years in those not exposed to protease inhibitors to 6.01 per 1000 person-years in those exposed to protease inhibitors for more than 6 years. After adjustment for exposure to the other drug class and established cardiovascular risk factors (excluding lipid levels), the relative rate of myocardial infarction per year of protease-inhibitor exposure was 1.16 (95% confidence interval [CI], 1.10 to 1.23), whereas the relative rate per year of exposure to nonnucleoside reverse-transcriptase inhibitors was 1.05 (95% CI, 0.98 to 1.13). Adjustment for serum lipid levels further reduced the effect of exposure to each drug class to 1.10 (95% CI, 1.04 to 1.18) and 1.00 (95% CI, 0.93 to 1.09), respectively. CONCLUSIONS: Increased exposure to protease inhibitors is associated with an increased risk of myocardial infarction, which is partly explained by dyslipidemia. We found no evidence of such an association for nonnucleoside reverse-transcriptase inhibitors; however, the number of person-years of observation for exposure to this class of drug was less than that for exposure to protease inhibitors.

Integrity signals

Registry

Crossref · 10.1056/nejmoa062744

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,393
Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
CD4+ Count–Guided Interruption of Antiretroviral Treatment
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,250
Self-citation
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
El-Sadr, W. M., & The Data Collection On Adverse Events Of Anti-HIV Drugs (DAD) Study Group (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,677
Self-citation
Changing patterns of mortality across Europe in patients infected with HIV-1
Mocroft, A., Vella, S., Benfield, T., Chiesi, A., Miller, V., Gargalianos, P., Monforte, A. D., Yust, I., Bruun, J., Phillips, A. N., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03201-2 · Cited by 1,269
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
Friis‐Møller, N., Weber, R. K., Reiss, P., Thiébaut, R., Kirk, O., Monforte, A. D., Pradier, C., Morfeldt, L., Mateu, S., Law, M. G., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00010 · Cited by 1,076
Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults
Staszewski, S., Morales-Ramirez, J. O., Tashima, K. T., Rachlis, A., Skiest, D. J., Stanford, J., Stryker, R., Johnson, P. C., Labriola, D., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
Ledergerber, B., Egger, M., Opravil, M., Telenti, A., Hirschel, B. J., Battegay, M., Vernazza, P., Sudre, P., Flepp, M., Furrer, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)01122-8 · Cited by 906
Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
Grünfeld, C., Pang, M., Doerrler, W. T., Shigenaga, J. K., Jensen, P., & Feingold, K. R. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.5.1373735 · Cited by 845
Impact of HIV infection and HAART on serum lipids in men
Riddler, S. A. (2003) · JAMA · doi:10.1001/jama.289.22.2978 · Cited by 624

Show all 26 references

Research works printed but not linked: 3

10.1210/jc.74.5.1045 · DOI
Phillips AN, Carr A, Neuhaus J, et al. Interruption of ART and risk of cardiovascular disease: findings from SMART. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 26, 2007. abstract. (Accessed March 29, 2007, athttp://www.retroconference.org/2007/abstracts/28863.htm.)
Sabin C, Morfeldt L, Friis-Møller N, et al. Changes over time in antiretroviral therapy (ART) use and risk factors for cardiovascular disease (CVD) in the D:A:D study. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 25, 2005. abstract. (Accessed March 29, 2007, athttp://www.retroconference.org/2005/cd/abstracts/25243.htm.)

Sorted by citations

Antiretroviral Treatment of Adult HIV Infection
Thompson, M., Aberg, J. A., Hoy, J., Telenti, A., Benson, C., Cahn, P. E., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,493
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182776f83 · Cited by 2,419
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.013 · Cited by 1,583
HIV Infection, Inflammation, Immunosenescence, and Aging
Deeks, S. G. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-042909-093756 · Cited by 1,349
HIV Infection and the Risk of Acute Myocardial Infarction
Freiberg, M. S., Chang, C.-C. H., Kuller, L. H., Skanderson, M., Lowy, E., Kraemer, K. L., Butt, A. A., Goetz, M. B., Leaf, D. A., Oursler, K. A., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.3728 · Cited by 1,340
. Premature Age-Related Comorbidities Among HIV-Infected Persons Compared with the General Population.
Guaraldi, G., Orlando, G., Zona, S., Menozzi, M., Carli, F., Garlassi, E., Berti, A., Rossi, E., Roverato, A., & Palella, F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir627 · Cited by 1,331
Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis
Shah, A. S. V., Stelzle, D., Lee, K. K., Beck, E. J., Alam, S., Clifford, S., Longenecker, C. T., Strachan, F., Bagchi, S., Whiteley, W., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033369 · Cited by 975
Endothelial dysfunction and vascular disease - a 30th anniversary update
Vanhoutte, P. M., Shimokawa, H., Feletou, M., & Tang, E. H. C. (2017) · Acta Physiologica · doi:10.1111/apha.12646 · Cited by 937
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
‡ (2008) · The Lancet · doi:10.1016/s0140-6736(08)60423-7 · Cited by 918
Future challenges for clinical care of an ageing population infected with HIV: a modelling study
Smit, M., Brinkman, K., Geerlings, S. E., Smit, C., Thyagarajan, K., van Sighem, A., de Wolf, F., & Hallett, T. B. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00056-0 · Cited by 943
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845
Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Aberg, J. A., Kaplan, J. E., Libman, H., Emmanuel, P. J., Anderson, J., Stone, V. E., Oleske, J. M., Currier, J. S., & Gallant, J. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605292 · Cited by 831
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
Anderson, T. J., Grégoire, J. C., Hegele, R. A., Couture, P., Mancini, G. B. J., McPherson, R., Francis, G. A., Poirier, P., Lau, D. C. W., Grover, S. A., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.11.032 · Cited by 780
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations
Genest, J. J., McPherson, R., Frohlich, J. J., Anderson, T. J., Campbell, N. R. C., Carpentier, A. C., Couture, P., Dufour, R., Fodor, G. J., Francis, G. A., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70715-9 · Cited by 765
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies
Sterne, J. A. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60612-7 · Cited by 748
Improving the prevention and management of chronic disease in low-income and middle-income countries: a priority for primary health care
Beaglehole, R., Epping-Jordan, J., Patel, V., Chopra, M., Ebrahim, S., Kidd, M., & Haines, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61404-x · Cited by 684
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.
Deeks, S. G., & Phillips, A. N. (2009) · BMJ · doi:10.1136/bmj.a3172 · Cited by 704
Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association
Feinstein, M. J., Hsue, P. Y., Benjamin, L. A., Bloomfield, G. S., Currier, J. S., Freiberg, M. S., Grinspoon, S. K., Levin, J., Longenecker, C. T., & Post, W. S. (2019) · Circulation · doi:10.1161/cir.0000000000000695 · Cited by 673
HIV infection
Deeks, S. G., Overbaugh, J. M., Phillips, A. N., & Buchbinder, S. P. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 718
Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study
Worm, S. W., Sabin, C. A., Weber, R. K., Reiss, P., El-Sadr, W. M., Dabis, F., Wit, S. D., Law, M. G., Monforte, A. D., Friis‐Møller, N., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/649897 · Cited by 644
Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health
Fuster, V., & Kelly, B. B. (2010) · Cited by 611
Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel
Thompson, M., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., Orrell, C., Altice, F. L., Bangsberg, D. R., Bartlett, J. G., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-11-201206050-00419 · Cited by 585
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
Broder, S. E. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.002 · Cited by 521
Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals
Duprez, D. A., Neuhaus, J., Kuller, L. H., Tracy, R. P., Belloso, W. H., Wit, S. D., Drummond, F., Lane, H. C., Ledergerber, B., Lundgren, J. D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044454 · Cited by 536
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Molina, J., Andrade-Villanueva, J. F., Echevarria, J. I., Chetchotisakd, P., Corral, J. A., David, N., Moyle, G. J., Mancini, M., Percival, L., Yang, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61081-8 · Cited by 484
Pathogenic Mechanisms of HIV Disease
Moir, S. L., Chun, T., & Fauci, A. S. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130254 · Cited by 520
Antiretroviral therapy and management of HIV infection
Volberding, P. A., & Deeks, S. G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60676-9 · Cited by 461
The design of drugs for HIV and HCV
Clercq, E. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2424 · Cited by 429
Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2008) · The Journal of Infectious Diseases · doi:10.1086/586713 · Cited by 400
Self-citation
Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-1-201307020-00645 · Cited by 393
Diagnosis of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons
Qaseem, A., Fihn, S. D., Williams, S., Dallas, P., Owens, D. K., & Shekelle, P. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00010 · Cited by 391
Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study
Friis-Møller, N., Thiébaut, R., Reiss, P., Weber, R., D'Arminio Monforte, A., De Wit, S., El-Sadr, W., Fontas, E., Worm, S., Kirk, O., et al. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328336a150 · Cited by 384
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
Baker, J. V., Peng, G., Rapkin, J. S., Abrams, D. I., Silverberg, M. J., MacArthur, R. D., Cavert, W. P., Henry, W. K., & Neaton, J. D. (2008) · AIDS · doi:10.1097/qad.0b013e3282f7cb76 · Cited by 372
Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral Therapy
Currier, J. S., Lundgren, J. D., Carr, A. D., Klein, D. B., Sabin, C. A., Sax, P. E., Schouten, J. T., Smieja, M., & for Working Group 2 (2008) · Circulation · doi:10.1161/circulationaha.107.189624 · Cited by 367
A Review of the Toxicity of HIV Medications
Margolis, A. M., Heverling, H., Pham, P. A., & Stolbach, A. I. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0325-8 · Cited by 350
Comparison of Ischemic Stroke Incidence in HIV-Infected and Non–HIV-Infected Patients in a US Health Care System
Chow, F. C., Regan, S., Feske, S. K., Meigs, J. B., Grinspoon, S. K., & Triant, V. A. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31825c7f24 · Cited by 354
Cohort Profile: The Swiss HIV Cohort Study
Study, T. S. H. C., Schoeni‐Affolter, F., Ledergerber, B., Rickenbach, M., Rudin, C., Günthard, H. F., Telenti, A., Furrer, H., Yerly, S., & Francioli, P. B. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyp321 · Cited by 347
Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The “Mortalité 2000 and 2005” Surveys (ANRS EN19 and Mortavic)
Lewden, C., May, T., Rosenthal, É., Burty, C., Bonnet, F., Costagliola, D. G., Jougla, É., Semaille, C. H., Morlat, P., Salmon, D., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31817efb54 · Cited by 339
Associations Between HIV Infection and Subclinical Coronary Atherosclerosis
Post, W. S., Budoff, M. J., Kingsley, L., Palella, F. J., Witt, M. D., Li, X., George, R. T., Brown, T. T., & Jacobson, L. P. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1754 · Cited by 332
Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study
Obel, N., Thomsen, H. F., Kronborg, G., Larsen, C. S., Hildebrandt, P. R., Sørensen, H. T., & Gerstoft, J. (2007) · Clinical Infectious Diseases · doi:10.1086/518285 · Cited by 331
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients
Groups, T. S. A. T. D. S. (2008) · AIDS · doi:10.1097/qad.0b013e32830fe35e · Cited by 327
HIV drug development: the next 25 years
Flexner, C. W. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2336 · Cited by 317
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Eron, J. J., Young, B., Cooper, D. A., Youle, M. S., DeJesus, E., Andrade-Villanueva, J. F., Workman, C., Zajdenverg, R., Fätkenheuer, G., Berger, D. S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62041-9 · Cited by 316
Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV
Falutz, J., Allas, S., Blot, K. H., Potvin, D., Kotler, D. P., Somero, M. S., Berger, D., Brown, S., Richmond, G. J., Fessel, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072375 · Cited by 311
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 345
Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus–Infected Patients A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4 Antiretroviral Drugs, Risk of MI, and HIV
Lang, S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.197 · Cited by 303
Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral Therapy
Torriani, F. J., Komarow, L., Parker, R. A., Cotter, B. R., Currier, J. S., Dubé, M. P., Fichtenbaum, C. J., Gerschenson, M., Mitchell, C. K. C., Murphy, R. L., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.049 · Cited by 300
Review: Viral infections and mechanisms of thrombosis and bleeding
Goeijenbier, M., Wissen, M. V., van de Weg, C., Jong, E., Gerdes, V. E. A., Meijers, J. C. M., Brandjes, D. P. M., & Gorp, E. C. M. V. (2012) · Journal of Medical Virology · doi:10.1002/jmv.23354 · Cited by 302
Low CD4+T Cell Count Is a Risk Factor for Cardiovascular Disease Events in the HIV Outpatient Study
Lichtenstein, K. A., Armon, C., Buchacz, K. A., Chmiel, J. S., Buckner, K., Tedaldi, E., Wood, K. C., Holmberg, S. D., & Brooks, J. T. (2010) · Clinical Infectious Diseases · doi:10.1086/655144 · Cited by 300
Ageing and inflammation in patients with HIV infection
Nasi, M., De Biasi, S., Gibellini, L., Bianchini, E., Pecorini, S., Bacca, V, Guaraldi, G., Mussini, C., Pinti, M., & Cossarizza, A. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12814 · Cited by 277
Association Between HIV Infection, Antiretroviral Therapy, and Risk of Acute Myocardial Infarction: A Cohort and Nested Case–Control Study Using Québec's Public Health Insurance Database
Durand, M., Sheehy, O., Baril, J.-G., LeLorier, J., & Tremblay, C. L. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31821d33a5 · Cited by 281
Adiposity and Insulin Resistance in Humans: The Role of the Different Tissue and Cellular Lipid Depots
HOCKING, S. L., Samocha‐Bonet, D., Milner, K., Greenfield, J. R., & Chisholm, D. J. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1041 · Cited by 295
Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries
Patel, P., Rose, C. E., Collins, P. Y., Nuche‐Berenguer, B., Sahasrabuddhe, V. V., Peprah, E. K., Vorkoper, S., Pastakia, S. D., Rausch, D. M., & Levitt, N. S. (2018) · AIDS · doi:10.1097/qad.0000000000001888 · Cited by 281
Immunologic Basis of Cardiovascular Disease in HIV-Infected Adults
Hsue, P. Y., Deeks, S. G., & Hunt, P. W. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis200 · Cited by 281
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men
Kaplan, R. C., Kingsley, L., Gange, S. J., Benning, L., Jacobson, L. P., Lazar, J., Anastos, K., Tien, P. C., Sharrett, A. R., & Hodis, H. N. (2008) · AIDS · doi:10.1097/qad.0b013e328300581d · Cited by 265
HIV and Coronary Heart Disease
Boccara, F., Lang, S., Meuleman, C., Éderhy, S., Mary‐Krause, M., Costagliola, D. G., Capeau, J., & Cohen, A. A. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.063 · Cited by 261
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment
Haubrich, R., Riddler, S. A., DiRienzo, A. G., Komarow, L., Powderly, W. G., Klingman, K. L., Garren, K. W., Butcher, D. L., Rooney, J. F., Haas, D. W., et al. (2009) · AIDS · doi:10.1097/qad.0b013e32832b4377 · Cited by 253
Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study
Molina, J., Andrade-Villanueva, J. F., Echevarría, J., Chetchotisakd, P., Corral, J. A., David, N., Moyle, G. J., Mancini, M., Percival, L., Yang, R., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181c990bf · Cited by 253
An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study
Friis‐Møller, N., Ryom, L., Smith, C. J., Weber, R. K., Reiss, P., Dabis, F., Wit, S. D., Monforte, A. D., Kirk, O., Fontas, É., et al. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315579291 · Cited by 242
Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial
Phillips, A. N., Carr, A. D., Neuhaus, J., Visnegarwala, F., Prineas, R. J., Burman, W. J., Williams, I. G., Drummond, F., Duprez, D. A., Belloso, W. H., et al. (2008) · Antiviral Therapy · doi:10.1177/135965350801300215 · Cited by 240
Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection
Triant, V. A., Perez, J., Regan, S., Massaro, J. M., Meigs, J. B., Grinspoon, S. K., & D’Agostino, R. B. (2018) · Circulation · doi:10.1161/circulationaha.117.028975 · Cited by 237
Cardiovascular Disease and HIV Infection
Triant, V. A. (2013) · Current HIV/AIDS Reports · doi:10.1007/s11904-013-0168-6 · Cited by 236
When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries
The HIV-CAUSAL Collaboration* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-8-201104190-00001 · Cited by 234
Inflammation, immune activation, and cardiovascular disease in HIV
Nou, E., Lo, J., & Grinspoon, S. K. (2016) · AIDS · doi:10.1097/qad.0000000000001109 · Cited by 233
Inflammation, Immune Activation, and Antiretroviral Therapy in HIV
Hileman, C. O., & Funderburg, N. (2017) · Current HIV/AIDS Reports · doi:10.1007/s11904-017-0356-x · Cited by 233
HIV infection and coronary heart disease: mechanisms and management
Hsue, P. Y., & Waters, D. D. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0219-9 · Cited by 237
State of the Science Conference
Grinspoon, S. K., Grünfeld, C., Kotler, D. P., Currier, J. S., Lundgren, J. D., Dubé, M. P., Lipshultz, S. E., Hsue, P. Y., Squires, K., Schambelan, M., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.189622 · Cited by 230
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy
Marin, B., Thiébaut, R., Bucher, H. C., Rondeau, V., Costagliola, D. G., Dorrucci, M., Hamouda, O., Prins, M., Walker, A. S., Porter, K., et al. (2009) · AIDS · doi:10.1097/qad.0b013e32832e9b78 · Cited by 229
British HIV Association guidelines for the treatment of HIV ‐1‐positive adults with antiretroviral therapy 2012
Writing Group, Williams, I. G., Churchill, D. R., Anderson, J., Boffito, M., Bower, M., Cairns, G., Cwynarski, K., Edwards, S., Fidler, S. J., et al. (2012) · HIV Medicine · doi:10.1111/j.1468-1293.2012.01029.x · Cited by 225
Risk of Heart Failure With Human Immunodeficiency Virus in the Absence of Prior Diagnosis of Coronary Heart Disease
Butt, A. A., Chang, C. H., Kuller, L. H., Goetz, M. B., Leaf, D. A., Rimland, D., Gibert, C. L., Oursler, K. K., Rodriguez‐Barradas, M. C., Lim, J. K., et al. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.151 · Cited by 221
Ten-Year Predicted Coronary Heart Disease Risk in HIV-Infected Men and Women
Kaplan, R. C., Kingsley, L., Sharrett, A. R., Li, X., Lazar, J., Tien, P. C., Mack, W. J., Cohen, M. H., Jacobson, L. P., & Gange, S. J. (2007) · Clinical Infectious Diseases · doi:10.1086/521935 · Cited by 219
Plant glutaredoxins: still mysterious reducing systems
Rouhier, N., Gelhaye, É., & Jacquot, J. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-3410-y · Cited by 219
Response to Newly Prescribed Lipid-Lowering Therapy in Patients With and Without HIV Infection
Silverberg, M. J., Leyden, W., Hurley, L., Go, A. S., Quesenberry, C. P., Klein, D., & Horberg, M. A. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-5-200903030-00006 · Cited by 218
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV*
Lundgren, J., Battegay, M., Behrens, G., De Wit, S., Guaraldi, G., Katlama, C., Martinez, E., Nair, D., Powderly, W., Reiss, P., et al. (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2007.00534.x · Cited by 210
Risk of Cardiovascular Disease from Antiretroviral Therapy for HIV: A Systematic Review
Bavinger, C., Bendavid, E., Niehaus, K. E., Olshen, R. A., Olkin, I., H, V. S. M. P., Wein, N., Holodniy, M., Hou, N., Owens, D. K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059551 · Cited by 205
Chronic noncommunicable diseases and HIV-AIDS on a collision course: relevance for health care delivery, particularly in low-resource settings—insights from South Africa
Levitt, N. S., Steyn, K., Dave, J. A., & Bradshaw, D. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.019075 · Cited by 205
HIV Infection and Older Americans: The Public Health Perspective
Brooks, J. T., Buchacz, K. A., Gebo, K. A., & Mermin, J. (2012) · American Journal of Public Health · doi:10.2105/ajph.2012.300844 · Cited by 204
B ritish HIV A ssociation guidelines for the routine investigation and monitoring of adult HIV ‐1‐infected individuals 2011
Asboe, D., Aitken, C., Boffito, M., Booth, C. L., Cane, P., Fakoya, A. O., Geretti, A. M., Kelleher, P., Mackie, N., Muir, D., et al. (2011) · HIV Medicine · doi:10.1111/j.1468-1293.2011.00971.x · Cited by 197
Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection
Ford, E. S., Greenwald, J. H., Richterman, A. G., Rupert, A. W., Dutcher, L. S., Badralmaa, Y., Natarajan, V., Rehm, C. A., Hadigan, C. M., & Sereti, I. (2010) · AIDS · doi:10.1097/qad.0b013e32833ad914 · Cited by 195
British HIV Association guidelines for the treatment of HIV ‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.)
Writing Group, Williams, I. G., Churchill, D. R., Anderson, J., Boffito, M., Bower, M., Cairns, G., Cwynarski, K., Edwards, S., Fidler, S. J., et al. (2013) · HIV Medicine · doi:10.1111/hiv.12119 · Cited by 194
Cause-Specific Life Expectancies After 35 Years of Age for Human Immunodeficiency Syndrome-Infected and Human Immunodeficiency Syndrome-Negative Individuals Followed Simultaneously in Long-term Cohort Studies, 1984–2008
Wada, N., Jacobson, L. P., Cohen, M. H., French, A. L., Phair, J., & Muñoz, Á. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws321 · Cited by 193
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
Martínez, E., Larrousse, M., Llibre, J. M., Gutiérrez, F., Saumoy, M., Antela, A., Knobel, H., Murillas, J., Berenguer, J., Pich, J., et al. (2010) · AIDS · doi:10.1097/qad.0b013e32833a608a · Cited by 192
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
Aboud, M., Kaplan, R., Lombaard, J. J., Zhang, F., Hidalgo, J. A. M., Mamedova, E., Losso, M. H., Chetchotisakd, P., Brites, C. R., Sievers, J., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30036-2 · Cited by 192
The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure
Campbell, J. H., Hearps, A. C., Martin, G. E., Williams, K. C., & Crowe, S. M. (2014) · AIDS · doi:10.1097/qad.0000000000000408 · Cited by 195
Human Immunodeficiency Virus in an Aging Population, a Complication of Success
Kirk, J. B., & Goetz, M. B. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02494.x · Cited by 181
Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects
Brothers, C. H., Hernández, J. E., Cutrell, A. G., Curtis, L. D., Ait‐Khaled, M., Bowlin, S. J., Hughes, S. H., Yeo, J., & Lapierre, D. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31819ff0e6 · Cited by 181
Monocytes as Regulators of Inflammation and HIV-Related Comorbidities during cART
Anzinger, J. J., Butterfield, T. R., Angelovich, T. A., Crowe, S. M., & Palmer, C. S. (2014) · Journal of Immunology Research · doi:10.1155/2014/569819 · Cited by 185
Incomplete Immune Recovery in HIV Infection: Mechanisms, Relevance for Clinical Care, and Possible Solutions
Gaardbo, J. C., Hartling, H. J., Gerstoft, J., & Nielsen, S. D. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/670957 · Cited by 183
The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality
Kumar, S., & Samaras, K. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00705 · Cited by 185
Immunodeficiency and Risk of Myocardial Infarction Among HIV-Positive Individuals With Access to Care
Silverberg, M. J., Leyden, W. A., Xu, L., Horberg, M. A., Chao, C., Towner, W. J., Hurley, L. B., Quesenberry, C. P., & Klein, D. B. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000009 · Cited by 180
Understanding and managing the adverse effects of antiretroviral therapy
Hawkins, T. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.016 · Cited by 177
HIV and HAART-Associated Dyslipidemia
Feeney, E. R., & Mallon, P. W. G. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010049 · Cited by 173
High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy
Mondy, K. E., Gottdiener, J. S., Overton, E. T., Henry, K., Bush, T. J., Conley, L. J., Hammer, J., Carpenter, C. C. J., Kojic, E. M., Patel, P., et al. (2010) · Clinical Infectious Diseases · doi:10.1093/cid/ciq066 · Cited by 172
Association of Immunologic and Virologic Factors With Myocardial Infarction Rates in a US Healthcare System
Triant, V. A., Regan, S., Lee, H., Sax, P. E., Meigs, J. B., & Grinspoon, S. K. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181f4b752 · Cited by 171
Association Between Kidney Function and Albuminuria With Cardiovascular Events in HIV-Infected Persons
Choi, A. I., Li, Y., Deeks, S. G., Grünfeld, C., Volberding, P. A., & Shlipak, M. G. (2010) · Circulation · doi:10.1161/circulationaha.109.898585 · Cited by 169
HIV Infection and Obesity: Where Did All the Wasting Go?
Tate, T. P., Willig, A. L., Willig, J. H., Raper, J. L., Moneyham, L. L., Kempf, M.-C., Saag, M. S., & Mugavero, M. J. (2012) · Antiviral Therapy · doi:10.3851/imp2348 · Cited by 175
Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients
Hsue, P. Y., Hunt, P. W., Wu, Y., Schnell, A., Ho, J. E., Hatano, H., Xie, Y., Martin, J. N., Ganz, P., & Deeks, S. G. (2009) · AIDS · doi:10.1097/qad.0b013e32832e7140 · Cited by 168
Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort
Sliwa, K. S., Carrington, M. J., Becker, A., Thienemann, F., Ntsekhe, M., & Stewart, S. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr398 · Cited by 166
Short‐term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D : A : D study
Achhra, A. C., Mocroft, A., Reiss, P., Sabin, C. A., Ryom, L., Wit, S. D., Smith, C. J., Monforte, A. D., Phillips, A. N., Weber, R. K., et al. (2015) · HIV Medicine · doi:10.1111/hiv.12294 · Cited by 163
Self-citation

Authors: The DAD Study Group
Corresponding author: The DAD Study Group
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-04-26
Volume: 356
Issue: 17
Pages: 1723-1735
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa062744
OpenAlex: W1767400858
Cited by: 1,521
References: 26
Citations by year: 2026: 17 · 2025: 22 · 2024: 19 · 2023: 30 · 2022: 30 · 2021: 45 · 2020: 39 · 2019: 49 · 2018: 64 · 2017: 51 · 2016: 81 · 2015: 92 · 2014: 87 · 2013: 114 · 2012: 130
FWCI: 185.17
Type: journal article
Language: en
Open access: green
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Digital Access to Libraries (submittedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Columbia Academic Commons (Columbia University)
Funders: National Institute of Allergy and Infectious Diseases (U01AI046362, U01AI042170)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: myocardial infarction, antiretroviral drugs, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, HIV infection, cardiovascular risk, dyslipidemia, serum lipids, drug exposure duration
MeSH terms: Adult, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Risk, HIV-1, HIV Infections, Incidence, Poisson Distribution, HIV Protease Inhibitors, Reverse Transcriptase Inhibitors, Observation, Anti-Retroviral Agents, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks